文献速递炎症性肠病

MEDI2070(一种抗白细胞介素23抗体)治疗中重度克罗恩病的疗效与安全性:一项2a期研究

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.
PubMed 文献 · Gastroenterology · 2017-04-05

这项双盲、安慰剂对照2a期研究纳入119例经肿瘤坏死因子拮抗剂治疗失败的中重度克罗恩病成人患者,随机接受MEDI2070 700 mg或安慰剂静脉给药。第8周临床应答率MEDI2070组为49.2%,安慰剂组为26.7%,绝对差异22.5%(95%CI 5.6%-39.5%,P=.010);最常见不良事件为头痛和鼻咽炎。

要点

  • 第8周临床应答率MEDI2070组49.2% vs 安慰剂组26.7%,绝对差异22.5%(95%CI 5.6%-39.5%,P=.010)。
  • 第24周临床应答率:持续开放标签MEDI2070组为53.8%,双盲期安慰剂后转开放标签MEDI2070组为57.7%。
  • 基线血清IL22浓度较高与MEDI2070较安慰剂更可能应答相关。

核心结论

  • 在经肿瘤坏死因子拮抗剂治疗失败的中重度克罗恩病患者中,MEDI2070治疗8周和24周与临床改善相关。

研究设计与样本

  • 双盲、安慰剂对照2a期研究,纳入119例经肿瘤坏死因子拮抗剂治疗失败的中重度克罗恩病成人患者。
  • 患者按1:1随机分配至MEDI2070 700 mg组或安慰剂组,第0周和第4周静脉给药。
  • 第12周至第112周,患者每4周皮下接受开放标签MEDI2070 210 mg。
  • 采用克罗恩病活动指数评估疾病活动度。

主要发现

  • 主要结局第8周临床应答(CD活动指数较基线下降100分或临床缓解,即CD活动指数<150)率:MEDI2070组49.2%(n=59)vs 安慰剂组26.7%(n=60),绝对差异22.5%(95%CI 5.6%-39.5%,P=.010)。
  • 第24周临床应答率:持续接受开放标签MEDI2070组为53.8%,双盲期接受安慰剂后转开放标签MEDI2070组为57.7%。
  • 最常见不良事件为头痛和鼻咽炎。
  • 基线血清IL22(一种表达受IL23诱导的细胞因子)浓度较高与MEDI2070较安慰剂更可能应答相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). We analyzed its safety and efficacy in treatment of CD in a phase 2a study. METHODS: We conducted a double-blind, placebo-controlled study of 119 adults with moderate to severe CD failed by treatment with tumor necrosis factor antagonists. Patients were randomly assigned (1:1) to groups given MEDI2070 (700 mg) or placebo intravenously at weeks 0 and 4. Patients received open-label MEDI2070 (210 mg) subcutaneously every 4 weeks from weeks 12 to 112. The CD Activity Index was used to measure disease activity. RESULTS: The primary outcome, clinical response (either a 100-point decrease in CD Activity Index score from baseline or clinical remission, defined as CD Activity Index score <150) at week 8 occurred in 49.2% of patients receiving MEDI2070 (n = 59) compared with 26.7% receiving placebo (n = 60; absolute difference, 22.5%; 95% confidence interval, 5.6%-39.5%; P = .010). Clinical response at week 24 occurred in 53.8% of patients who continued to receive open-label MEDI2070 and in 57.7% of patients who had received placebo during the double-blind period and open-label MEDI2070 thereafter. The most common adverse events were headache and nasopharyngitis. Higher baseline serum concentrations of IL22, a cytokine whose expression is induced by IL23, were associated with greater likelihood of response to MEDI2070 compared with placebo. CONCLUSIONS: In a phase 2a trial of patients with moderate to severe Crohn's disease who had failed treatment with tumor necrosis factor antagonists, 8 and 24 weeks of treatment with MEDI2070 were associated with clinical improvement. ClinicalTrials.gov ID: NCT01714726.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Sands BE, Chen J, Feagan BG, et al. Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology. 2017. PMID: 28390867. doi:10.1053/j.gastro.2017.03.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。